Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: A Second Straight Burst Of FDA Approvals

Executive Summary

The latest drug approval and development news from our US FDA Performance Tracker.

Advertisement

Related Content

Novel Biologics Will Get Suffixes (Or At Least One Did)
FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
Keeping Track: Breakthrough Therapies Becoming Breakthrough Applications For Tezacaftor, Burosumab, Emicizumab
Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed
Bluebird Flies On 100% Response Rate For Anti-BCMA CAR-T
Akcea Faces Tricky Risk/Benefit Scenario In Orphan Disease FCS
Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121994

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel